drugset / Trial / NCT07034859
Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
Phase 4
Enrolling by invitation
30 enrolled
National Taiwan University Hospital
National Taiwan University · collabNational Taiwan University Hospital Beihu Branch · collabNational Taiwan University Hospital Hsin-Chu Branch · collabNational Taiwan University Hospital, Yun-Lin Branch · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn if Cabergoline (Dostinex), a dopamine agonist which has been widely used to treat hyperprolactinemia, prolactinoma for many years, works to treat nonfunctioning pituitary adenoma (NFPA) in adults. The main questions it aims to answer are: Does cabergoline reduce the size of NFPA effectively when used as primary therapy? Participants will: Be 1:1 randomized into two groups. Either to take cabergoline or none for 48 weeks, Visit the clinic every 12 weeks for checkups and tests, Undergo scheduled imaging studies, Magnetic Resonance Imaging (MRI) to measure the change of tumor size.
Timeline
- Start
- 2024-05-20
- Primary completion
- 2028-10-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabergoline | Small molecule | 2 mg | Oral |